Quick Answer
COLLEGIUM PHARMACEUTICAL, INC reported Net Income Loss of $62.87 million for the year ending 2025.
- COLLEGIUM PHARMACEUTICAL, INC showed a decrease of -9.1% in Net Income Loss from 2024 to 2025.
- This data is from COLLEGIUM PHARMACEUTICAL, INC's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2017: -$17.40 million | Q1 2018: -$18.65 million | Q2 2018: -$13.06 million | Q3 2018: -$16.50 million | Q4 2018: $9.09 million | Q1 2019: -$9.70 million | Q2 2019: -$4.71 million | Q3 2019: -$6.11 million | Q4 2019: -$2.20 million | Q1 2020: $450.0 thousand | Q2 2020: $8.06 million | Q3 2020: $11.29 million | Q4 2020: $6.96 million | Q1 2021: $15.66 million | Q2 2021: $72.84 million | Q3 2021: $8.05 million | Q4 2021: -$25.03 million | Q1 2022: -$13.07 million | Q2 2022: -$5.19 million | Q3 2022: $457.0 thousand | Q4 2022: -$7.20 million | Q1 2023: -$17.43 million | Q2 2023: $13.01 million | Q3 2023: $20.63 million | Q4 2023: $31.94 million | Q1 2024: $27.71 million | Q2 2024: $19.61 million | Q3 2024: $9.34 million | Q4 2024: $12.54 million | Q1 2025: $2.42 million | Q2 2025: $11.98 million | Q3 2025: $31.51 million | Q4 2025: $16.96 million.
- Over the full 13 years of available data (2013 to 2025), COLLEGIUM PHARMACEUTICAL, INC's Net Income Loss has grown by 488.2%.
- Historical annual values: Fiscal year 2025: $62.87 million | Fiscal year 2024: $69.19 million | Fiscal year 2023: $48.16 million | Fiscal year 2022: -$25.00 million | Fiscal year 2021: $71.52 million | Fiscal year 2020: $26.75 million | Fiscal year 2019: -$22.72 million | Fiscal year 2018: -$39.13 million | Fiscal year 2017: -$74.87 million | Fiscal year 2016: -$94.18 million | Fiscal year 2015: -$27.26 million | Fiscal year 2014: -$17.92 million | Fiscal year 2013: -$16.20 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: